Privia Health Group, Inc. (NASDAQ:PRVA – Get Rating) Director William M. Sullivan sold 285,027 shares of the company’s stock in a transaction that occurred on Monday, November 21st. The shares were sold at an average price of $22.56, for a total transaction of $6,430,209.12. Following the completion of the transaction, the director now owns 5,887,466 shares in the company, valued at approximately $132,821,232.96. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Privia Health Group Price Performance
NASDAQ PRVA opened at $22.80 on Thursday. The company’s fifty day moving average is $32.02 and its two-hundred day moving average is $32.07. Privia Health Group, Inc. has a 52-week low of $17.99 and a 52-week high of $44.64. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -63.33 and a beta of 0.99.
Privia Health Group (NASDAQ:PRVA – Get Rating) last released its earnings results on Thursday, November 10th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $342.90 million for the quarter, compared to the consensus estimate of $323.66 million. Privia Health Group had a negative return on equity of 6.82% and a negative net margin of 3.02%. As a group, sell-side analysts expect that Privia Health Group, Inc. will post -0.25 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Privia Health Group
Analyst Ratings Changes
A number of equities analysts have recently weighed in on PRVA shares. Piper Sandler dropped their price target on shares of Privia Health Group to $42.00 in a research note on Thursday, November 17th. Canaccord Genuity Group cut their price target on Privia Health Group from $50.00 to $43.00 in a research note on Friday, November 11th. Canaccord Genuity Group dropped their price objective on Privia Health Group from $50.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, November 11th. SVB Leerink reduced their target price on shares of Privia Health Group from $46.00 to $39.00 and set an “outperform” rating for the company in a research note on Friday, November 11th. Finally, BTIG Research raised their price target on shares of Privia Health Group to $45.00 in a report on Monday, August 15th. Eleven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $41.08.
Privia Health Group Company Profile
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
- Get a free copy of the StockNews.com research report on Privia Health Group (PRVA)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.